thakker dhrien (30 resultados)

Condición: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

Condición: Brand New. New. US edition. Expediting shipping for all USA and Europe orders excluding PO Box. Excellent Customer Service.

Hardcover. Condición: Very Good. 2006. It's a well-cared-for item that has seen limited use. The item may show minor signs of wear. All the text is legible, with all pages included. It may have slight markings and/or highlighting.

Condición: very_good. Supports Goodwill of Silicon Valley job training programs. The cover and pages are in very good condition! The cover and any other included accessories are also in very good condition showing some minor use. The spine is straight, there are no rips tears or creases on the cover or the pages.

Condición: Used. pp. xiii + 482 2004th edition.

Condición: Used. pp. xiii + 482 Illus.

Condición: Used. pp. xiii + 482.

Condición: New. In.

Condición: New. In.

Hardcover. Condición: Very Good. Hardcover (no jacket; printed boards). Includes CD-ROM on inside rear board. Very good condition. Half-title page has partially separated from binding. Boards' leading corners are a little bumped and scuffed. Pages are clear. TA. Used.

Taschenbuch. Condición: Neu. Optimizing the "Drug-Like" Properties of Leads in Drug Discovery | Ronald Borchardt (u. a.) | Taschenbuch | x | Englisch | 2016 | Springer US | EAN 9781493950478 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.

Condición: New.

Hardcover. Condición: new. Hardcover. At a time when pharmaceutical companies have limited resources to develop newer and better drugs, they must continually evaluate the effectiveness and efficiency of their research and development process. This volume focuses on how to increase the efficiency of drug discovery and development. Written by experienced discovery scientists from diverse disciplines, including chemistry, drug metabolism, and development sciences, it details in silico, in vitro, and in vivo tools for prediction, measurement, and application of compound properties to select and improve potential drug candidates. At a time when pharmaceutical companies have limited resources to develop newer and better drugs, they must continually evaluate the effectiveness and efficiency of their research and development process. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.

Taschenbuch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, 'drug-like' properties refer to the molecule's physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development.

Buch. Condición: Neu. Druck auf Anfrage Neuware - Printed after ordering - Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, 'drug-like' properties refer to the molecule's physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development.

Condición: New. Editor(s): Borchardt, Ronald; Kerns, Edward H.; Lipinski, Christopher A.; Thakker, Dhrien R.; Wang, Binghe. Series: Biotechnology: Pharmaceutical Aspects. Num Pages: 482 pages, 121 black & white illustrations, 9 colour illustrations, 47 black & white tables, biograp. BIC Classification: MBGR1. Category: (P) Professional & Vocational. Dimension: 254 x 178 x 33. Weight in Grams: 1237. . 2005. 2004th Edition. hardcover. . . . .

Gebunden. Condición: New. Explores ways to increase the efficiency of drug discovery and developmentThis volume focuses on how to increase the efficiency of drug discovery and development. It is written by experienced discovery scientists from diverse disciplines, including c.

Hardcover. Condición: Brand New. 1st hardback/cd-rom edition. 512 pages. 10.00x7.00x1.25 inches. In Stock.

Hardcover. Condición: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

Hardcover. Condición: Brand New. 495 pages. 10.00x7.00x1.25 inches. In Stock.

Condición: New. Editor(s): Borchardt, Ronald; Kerns, Edward H.; Lipinski, Christopher A.; Thakker, Dhrien R.; Wang, Binghe. Series: Biotechnology: Pharmaceutical Aspects. Num Pages: 482 pages, 121 black & white illustrations, 9 colour illustrations, 47 black & white tables, biograp. BIC Classification: MBGR1. Category: (P) Professional & Vocational. Dimension: 254 x 178 x 33. Weight in Grams: 1237. . 2005. 2004th Edition. hardcover. . . . . Books ship from the US and Ireland.

Buch. Condición: Neu. Neuware - At a time when pharmaceutical companies have limited resources to develop newer and better drugs, they must continually evaluate the effectiveness and efficiency of their research and development process. This volume focuses on how to increase the efficiency of drug discovery and development. Written by experienced discovery scientists from diverse disciplines, including chemistry, drug metabolism, and development sciences, it details in silico, in vitro, and in vivo tools for prediction, measurement, and application of compound properties to select and improve potential drug candidates.

Condición: new. Questo è un articolo print on demand.

Taschenbuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book arises from a workshop organized by the American Association of Pharmaceutical Scientists entitled 'Optimizing the Drug-Like Properties of Leads in Drug Discovery,' which took place in Parsippany, NJ in September 2004. The workshop focused on the optimization of the drug-like properties of leads in drug discovery. The volume outlines strategies and methodologies designed to guide pharmaceutical and biotechnology companies through the drug discovery and development process. 524 pp. Englisch.

Buch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This book arises from a workshop organized by the American Association of Pharmaceutical Scientists entitled 'Optimizing the Drug-Like Properties of Leads in Drug Discovery,' which took place in Parsippany, NJ in September 2004. The workshop focused on the optimization of the drug-like properties of leads in drug discovery. The volume outlines strategies and methodologies designed to guide pharmaceutical and biotechnology companies through the drug discovery and development process. 524 pp. Englisch.

Buch. Condición: Neu. Optimizing the "Drug-Like" Properties of Leads in Drug Discovery | Ronald Borchardt (u. a.) | Buch | x | Englisch | 2006 | Springer New York | EAN 9780387340562 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu Print on Demand.

Buch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, ¿drug-like¿ properties refer to the molecule¿s physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 524 pp. Englisch.

Taschenbuch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Drug discovery and development is a very complex, costly, and ti- consuming process. Because of the uncertainties associated with predicting the pharmacological effects and the toxicity characteristics of new chemical entities in man, their clinical development is quite prone to failure. In recent years, phar- ceutical companies have come under increasing pressure to introduce new blockbuster drugs into the marketplace more rapidly. Companies have responded to these pressures by introducing new technologies and new strategies to expedite drug discovery and development. Drug discovery and development have traditionally been divided into three separate processes (i. e. , discovery research, preclinical development, and clinical development) that ideally should be integrated both organizationally and functionally. Instead, separate and distinct discovery research, preclinical development, and clinical development divisions were created within many companies during the 1980s and 1990s, Because of their isolation, scientists in the discovery research divisions often were advancing drug candidates into preclinical development that had marginal drug-like properties. For the purpose of this presentation, ¿drug-like¿ properties refer to the molecule¿s physicochemical, absorption-distribution-metabolism-excretion (ADME), and toxicological properties. Lacking optimal drug-like properties often caused these drug candidates to fail in preclinical or clinical development.Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 524 pp. Englisch.

Condición: New. Print on Demand.

Condición: New. PRINT ON DEMAND.